Wells Fargo analyst Tiago Fauth maintained a Buy rating on MannKind (MNKD – Research Report) yesterday and set a price target of $9.00.
Tiago Fauth has given his Buy rating due to a combination of factors that highlight MannKind’s promising growth potential and strategic advancements. The company is progressing well with its MNKD-101 program, with a significant portion of the anticipated sites activated and patients randomized, setting the stage for a key interim analysis in mid-2026. This inhaled formulation of clofazimine is expected to offer an effective treatment for NTM while potentially reducing severe side effects associated with oral delivery.
Furthermore, the MNKD-201 program is poised to advance in the latter half of 2025, offering a similar strategic advantage by delivering nintedanib directly to the lungs, which may bypass gastrointestinal side effects. MannKind’s strong revenue growth, driven by Tyvaso DPI royalties and a potential expansion of Afrezza into the pediatric market, underscores its robust growth profile. These elements, coupled with the market’s current focus on tangible revenue streams, suggest a promising outlook for MannKind, justifying the Buy rating.
In another report released yesterday, Wedbush also reiterated a Buy rating on the stock with a $11.00 price target.